The Europe Circulating Tumor Cell Market is expected to witness market growth of 13.0% CAGR during the forecast period (2024-2031).
The Germany market dominated the Europe Circulating Tumour Cell Market by country in 2023, and is expected to continue to be a dominant market till 2031; thereby, achieving a market value of $1.84 billion by 2031. UK market is exhibiting a CAGR of 12.1% during 2024-2031. Additionally, the France market is expected to experience a CAGR of 13.9% during 2024-2031.
The adoption of CTC-based technologies has grown significantly over the past few years, driven by advances in liquid biopsy techniques, an increasing understanding of cancer biology, and a rising demand for less invasive diagnostic methods. Significant breakthroughs in CTC isolation and detection technologies, such as microfluidics, immunomagnetic capture, and imaging techniques, have enabled the accurate and efficient collection of CTCs from blood samples.
Moreover, innovations in molecular analysis, such as next-generation sequencing (NGS) and single-cell RNA sequencing, have further enhanced the ability to profile CTCs and gain insights into their genetic makeup.
The rising incidence of prostate and bladder cancer in Europe is driving a growing demand for advanced diagnostic and monitoring solutions, such as circulating tumor cell technologies. With prostate cancer being the most common cancer among men and bladder cancer ranking fifth in terms of prevalence, there is an urgent need for effective early detection and non-invasive diagnostic methods.
The Germany market dominated the Europe Circulating Tumour Cell Market by country in 2023, and is expected to continue to be a dominant market till 2031; thereby, achieving a market value of $1.84 billion by 2031. UK market is exhibiting a CAGR of 12.1% during 2024-2031. Additionally, the France market is expected to experience a CAGR of 13.9% during 2024-2031.
The adoption of CTC-based technologies has grown significantly over the past few years, driven by advances in liquid biopsy techniques, an increasing understanding of cancer biology, and a rising demand for less invasive diagnostic methods. Significant breakthroughs in CTC isolation and detection technologies, such as microfluidics, immunomagnetic capture, and imaging techniques, have enabled the accurate and efficient collection of CTCs from blood samples.
Moreover, innovations in molecular analysis, such as next-generation sequencing (NGS) and single-cell RNA sequencing, have further enhanced the ability to profile CTCs and gain insights into their genetic makeup.
The rising incidence of prostate and bladder cancer in Europe is driving a growing demand for advanced diagnostic and monitoring solutions, such as circulating tumor cell technologies. With prostate cancer being the most common cancer among men and bladder cancer ranking fifth in terms of prevalence, there is an urgent need for effective early detection and non-invasive diagnostic methods.
List of Key Companies Profiled
- Qiagen N.V
- Greiner Bio-One International GmbH
- Sysmex Corporation
- Miltenyi Biotech B.V & Co kg
- Bio-Techne Corporation
- Ikonisys, Inc.
- Menarini Silicon Biosystems SpA
- LungLife AI Inc.
- Aviva Systems Biology Corporation
- ScreenCell
Market Report Segmentation
By Product
- Kits & Reagents
- Devices
- Blood Collection Tubes
By End User
- Research and Academic Institutes
- Hospital & Clinics
- Diagnostic Centers
By Specimen
- Blood
- Bone Marrow
- Other Specimen
By Technology
- CTC Detection & Enrichment Methods
- CTC Analysis
- CTC Direct Detection
By Application
- Research, Clinical
- Drug/Therapy Development
By Country
- Germany
- UK
- France
- Russia
- Spain
- Italy
- Rest of Europe
Table of Contents
Chapter 1. Market Scope & Methodology
Chapter 2. Market at a Glance
Chapter 3. Market Overview
Chapter 4. Europe Circulating Tumor Cell Market by Product
Chapter 5. Europe Circulating Tumor Cell Market by End User
Chapter 6. Europe Circulating Tumor Cell Market by Specimen
Chapter 7. Europe Circulating Tumor Cell Market by Technology
Chapter 8. Europe Circulating Tumor Cell Market by Application
Chapter 9. Europe Circulating Tumor Cell Market by Country
Chapter 10. Company Profiles
Companies Mentioned
- Qiagen N.V
- Greiner Bio-One International GmbH
- Sysmex Corporation
- Miltenyi Biotech B.V & Co kg
- Bio-Techne Corporation
- Ikonisys, Inc.
- Menarini Silicon Biosystems SpA
- LungLife AI Inc.
- Aviva Systems Biology Corporation
- ScreenCell
Methodology
LOADING...
